News

VaLogic Bio Acquires Facility Logix to Expand Life Sciences Facility Services

VaLogic Bio, a platform company of 424 Capital and a leading provider of compliance and SaaS services to the life sciences industry, proudly announces the acquisition of Facility Logix (FLGX), a renowned firm specializing in planning, developing, and project management for life sciences facilities. This acquisition aligns with VaLogic Bio’s strategic vision to enhance its capabilities and broaden its footprint in the life sciences sector.

With this acquisition, VaLogic Bio will leverage Facility Logix’s current service offerings to build a market-leading, full-service outsourced solutions platform. This platform aims to enable life science and biotechnology companies to remain GMP compliant through advisory, project management, procurement, technical equipment servicing, facility design/engineering and construction, environmental monitoring, and CQV services. These services will help clients run their labs and manufacturing suites more efficiently, allowing them to focus on advancing life-saving therapeutics. The combined company provides clients an unparalleled suite of services, from initial facility concept to operational readiness and ongoing compliance.

As part of the acquisition, Pat Larrabee, formerly the CEO and founder of Facility Logix, will become the Vice President of Advisory Services and join the VaLogic Bio leadership team.

The former Facility Logix team will continue to operate out of its Montgomery County, Maryland office in Burtonsville. With its proven track record, the team will continue to deliver high-quality, conflict-free services, ensuring a seamless and uninterrupted transition for existing clients and partners.

“The successful relationship between our firms has developed over many years of working together to support mutual clients in the Maryland market,” noted VaLogic Bio CEO Bill Robertson. “We are enthusiastic about permanently joining forces and further expanding our services and client base. Pat is well respected as a trusted advisor and leader and has deep national market knowledge.”

“We are excited about joining forces with VaLogic Bio,” commented Larrabee.

With the acquisition of Facility Logix, VaLogic Bio’s team now totals 72 employees, with offices in Texas and two offices in Maryland. This acquisition represents a significant step forward in VaLogic Bio’s unwavering commitment to simplifying compliance and ensuring peace of mind for life sciences organizations. By combining the strengths of both companies, VaLogic Bio is well-positioned to lead the industry in delivering innovative, efficient, and compliant solutions for life sciences facilities.

“I am very proud of our team’s capabilities and our portfolio of work over the past two decades,” said Larrabee. “And with the added capabilities of VaLogic Bio and the financial support of 424 Capital, we are poised to capture additional market share.”

For more information about the acquisition or to learn more about the services offered by VaLogic Bio, please visit www.valogicbio.com

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and